Opportunities & Partners
Within our therapeutic focus of immuno-oncology, F-star is pursuing additional select, strategic partnerships, to further leverage our powerful Modular Antibody Technology. Through the “plug-and-play” process, each Fcab can rapidly generate multiple bispecific antibodies, furthermore it can also be easily combined with other formats. This creates a multitude of opportunities for identifying novel and clinically meaningful biology.
Three asset-centric vehicles (“F-star Alpha Ltd.”, “F-star Beta Ltd.” and “F-star Gamma Ltd.”) have been established to create a flexible corporate structure which further enhances our ability to attract leading biopharmaceutical companies, through traditional license deals or straightforward option-to-buy asset acquisitions.
In 2014, Bristol-Myers Squibb obtained an option to acquire the first asset-centric vehicle, F-star Alpha, and gained worldwide rights to its lead asset: FS102.
F-star Beta holds an exclusive licence for the generation of Fcab and bispecific antibodies (mAb2) against certain oncology and immuno-oncology targets. F-star’s second asset-centric vehicle hosts the licencing agreement with AbbVie started in January 2016.
F-star Gamma holds the exclusive rights for the generation and delivery of Fcab and mAb² across the blood-brain barrier. The third asset-centric vehicle of the F-star family hosts the collaborative agreement with Denali Therapeutics initiated in August 2016.
We have four major pharmaceutical collaborations to leverage the power of F-star’s Fcab and Modular Antibody Technology platforms, to create and develop highly differentiated bispecific antibody products:
Merck Serono’s collaboration with F-star started in 2011. We are very pleased with how the partnership has developed since then, and highly appreciate the true collaborative spirit displayed by F-star’s scientists as well as its management. Creating an effective partnership means for us to create an open innovative culture which came true with F-star. The F-star team has clearly demonstrated it can deliver on the joint project plan. We are looking forward to advance our projects together.